Previous close | 1.1500 |
Open | 1.1500 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 22.50 |
Expiry date | 2024-10-18 |
Day's range | 1.1500 - 1.1500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral presentation in
Key Insights Significant control over Galapagos by retail investors implies that the general public has more power to...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune’s centralized manufacturing platform Initial in vitro testing of uza-cel produced on Ga